Papers/PMID:35277398
Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study.
BMJ open2022The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
myo-inositol — decreases HOMA-IR
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“We found significant reductions in HOMA-IR (MD −0.6; 95% CI −1.2 to 0.0) and levels of insulin (MD −2.69; 95% CI −5.26 to −0.18) in the intervention group versus control.”
Quoted verbatim from Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study.. - Study
- RCT
- Dose
- 2 g myo-inositol twice daily with 200 µg folic acid twice daily, until delivery
- Population
- Multiethnic pregnant women at high risk of gestational diabetes, 12+0 to 15+6 weeks' gestation at recruitment, UK; both arms took 200 µg folic acid twice daily, the control arm in a xylitol placebo powder; HOMA-IR measured at 28 weeks' gestation
Effect -0.6 mean difference, 95% CI -1.2 to 0
Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study.2022PMID:35277398Permalink